Back to search results

Liver Screening with FibroScan for Liver Disease Database

This study is creating a database of information from people with different types and stages of liver disease. Researchers will use a non-invasive device called FibroScan (vibration controlled transient elastography or VCTE) to measure liver stiffness and the amount of fat in the liver. This information, along with your medical history, will be added to a database for future research. You may be able to join if you are 18 or older and have known risk factors for fatty liver (steatosis) or liver scarring (fibrosis), a previous diagnosis of Non-Alcoholic Steatohepatitis (NASH) without current scoring, or other liver diseases like HCV. The main goal is to measure liver scarring in patients over 10 years to build this database.

Study design
This is an observational study aiming to enroll 1000 participants. It is not a treatment study but collects information for future research.
What's involved
You would have one FibroScan measurement. Researchers will also collect information about your demographics, medical history, and lab results.
Compensation
Not stated in the trial record.
Follow-up
Liver fibrosis measurements will be taken at 10 years, suggesting a long-term follow-up for data collection.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT02897908

Non-invasive Liver Screening Using FibroScan Device for Liver Disease Patients for the Steatosis/Fibrosis Database

Recruiting
Not specifiedAges 18+Observational
State University of New York at Buffalo
~1,000 participants
Updated 2026-06-22 on ClinicalTrials.gov
What's tested:vibration controlled transient elastography (VCTE)

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
measurement of fibrosis in patients with varying degrees of liver disease
Measured over 10 years

Conditions

Disease of Liver and Bile Duct

Explore related trials

Liver and Intrahepatic Bile Duct Disorder

NCT02897908

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Conventus Medical Office Building

    Buffalo, New Yorkstudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Who to contact

Ajay Chaudhuri, MD
[email protected]
716-907-1916
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Subjects with known, or suspected risk factors for steatosis (fat) or hepatic fibrosis
Subjects who have been previously diagnosed with Non-Alcoholic Steatohepatitis (NASH) but who do not have current steatosis (fat) or fibrosis scoring
Subjects who have other known liver diseases ie: HCV

Exclusion

Patients less than 18 years of age
Pregnancy
Patients that do not want to be contacted for consideration in future research studies.
Patients diagnosed with ascites or peritoneal dialysis
Body mass index (BMI) ≥40

What this trial measures

  • measurement of fibrosis in patients with varying degrees of liver disease10 years

    single event per patient with liver disease to measure degree of fibrosis concentration